In our study, independent of the well-recognized dominant driver genes RET and RAS, we expanded genetic drivers of MTC by identifying uncommon BRAF and NF1 alterations, whose downstream transcriptomic and proteomic consequences suggest potential oncogenic roles in this disease. This evidence concerns the gene RET and medullary thyroid gland carcinoma.